HRP20210577T1 - Sastavi i načini liječenja i sprječavanje upale - Google Patents

Sastavi i načini liječenja i sprječavanje upale Download PDF

Info

Publication number
HRP20210577T1
HRP20210577T1 HRP20210577TT HRP20210577T HRP20210577T1 HR P20210577 T1 HRP20210577 T1 HR P20210577T1 HR P20210577T T HRP20210577T T HR P20210577TT HR P20210577 T HRP20210577 T HR P20210577T HR P20210577 T1 HRP20210577 T1 HR P20210577T1
Authority
HR
Croatia
Prior art keywords
nrp1
polypeptide
soluble
cap
trap
Prior art date
Application number
HRP20210577TT
Other languages
English (en)
Croatian (hr)
Inventor
Przemyslaw SAPIEHA
Normand BEAULIEU
Original Assignee
Rsem, Limited Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rsem, Limited Partnership filed Critical Rsem, Limited Partnership
Publication of HRP20210577T1 publication Critical patent/HRP20210577T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
HRP20210577TT 2014-09-05 2015-09-08 Sastavi i načini liječenja i sprječavanje upale HRP20210577T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046459P 2014-09-05 2014-09-05
EP15838150.9A EP3189074B1 (en) 2014-09-05 2015-09-08 Compositions and methods for treating and preventing inflammation
PCT/CA2015/050862 WO2016033699A1 (en) 2014-09-05 2015-09-08 Compositions and methods for treating and preventing inflammation

Publications (1)

Publication Number Publication Date
HRP20210577T1 true HRP20210577T1 (hr) 2021-05-28

Family

ID=55438956

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210577TT HRP20210577T1 (hr) 2014-09-05 2015-09-08 Sastavi i načini liječenja i sprječavanje upale

Country Status (17)

Country Link
US (4) US10738122B2 (https=)
EP (1) EP3189074B1 (https=)
JP (3) JP6692816B2 (https=)
KR (2) KR102696275B1 (https=)
CN (2) CN113980116A (https=)
AU (1) AU2015311563B2 (https=)
CA (1) CA2960054C (https=)
DK (1) DK3189074T3 (https=)
ES (1) ES2865488T3 (https=)
HR (1) HRP20210577T1 (https=)
HU (1) HUE054204T2 (https=)
LT (1) LT3189074T (https=)
PL (1) PL3189074T3 (https=)
PT (1) PT3189074T (https=)
RS (1) RS61703B1 (https=)
SI (1) SI3189074T1 (https=)
WO (1) WO2016033699A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437462B2 (ja) 2013-02-21 2018-12-12 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
RS61703B1 (sr) 2014-09-05 2021-05-31 Rsem Limited Partnership Kompozicije i postupci za lečenje i prevenciju zapaljenja
DK3353196T5 (da) * 2015-09-22 2024-09-30 Inst Nat Sante Rech Med Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
US20200056186A1 (en) * 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
WO2018127599A1 (en) * 2017-01-09 2018-07-12 Secarna Pharmaceuticals Gmbh & Co Kg Oligonucleotides inhibiting the expression of nrp1
JP6470879B1 (ja) * 2017-03-08 2019-02-13 日清オイリオグループ株式会社 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物
WO2020225400A1 (en) * 2019-05-09 2020-11-12 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating eye or ocular diseases
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11066469B2 (en) 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
TWI859339B (zh) * 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
CN112641928A (zh) * 2019-10-11 2021-04-13 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
US20230181686A1 (en) * 2020-05-27 2023-06-15 Baylor College Of Medicine Compositions and methods for treating neovascularization and ischemic retinopathies by targeting angiogenesis and cholesterol transport
WO2021258218A1 (en) * 2020-06-26 2021-12-30 Semathera Inc. Use of soluble nrp1 polypeptides for the treatment of coronavirus infections
MX2023001366A (es) * 2020-07-31 2023-04-26 Pinetree Therapeutics Inc Péptidos de fusión de neuropilina y enzima conviertidora de angiotensina 2 para el tratamiento de infecciones virales.
IL311299A (en) 2021-09-08 2024-05-01 Univ Strasbourg Transmembrane peptide antagonists of plexin-A1 and their medical uses
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
AUPM516994A0 (en) 1994-04-20 1994-05-12 Gene Shears Pty. Limited An in vivo gene expression system
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
EP1418834A4 (en) * 2001-07-20 2007-04-04 Sinai School Medicine METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
EP1429801A1 (en) * 2001-09-26 2004-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neuropilin as a novel therapeutic target for modulation of immune reponses
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
US20090197794A1 (en) * 2005-07-13 2009-08-06 Aird William C Methods of Diagnosing and Treating an Inflammatory Response
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
CN103193888B (zh) * 2007-05-17 2015-09-09 健泰科生物技术公司 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构
KR101523788B1 (ko) 2007-05-17 2015-06-26 제넨테크, 인크. 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
WO2009060159A1 (en) 2007-11-08 2009-05-14 Medigene Limited Mutated ilt molecules
US20120322085A1 (en) 2009-11-05 2012-12-20 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
JP2013537172A (ja) * 2010-09-09 2013-09-30 トリフォイリウム エーピーエス 血管新生阻害剤の気道投与
JP6372040B2 (ja) 2013-02-06 2018-08-15 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
JP6437462B2 (ja) * 2013-02-21 2018-12-12 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
RS61703B1 (sr) 2014-09-05 2021-05-31 Rsem Limited Partnership Kompozicije i postupci za lečenje i prevenciju zapaljenja

Also Published As

Publication number Publication date
HUE054204T2 (hu) 2021-08-30
KR20240125991A (ko) 2024-08-20
KR20170044691A (ko) 2017-04-25
US10766964B2 (en) 2020-09-08
PT3189074T (pt) 2021-04-19
LT3189074T (lt) 2021-06-10
JP2023022308A (ja) 2023-02-14
WO2016033699A1 (en) 2016-03-10
CN107207577A (zh) 2017-09-26
US10738122B2 (en) 2020-08-11
EP3189074A4 (en) 2018-06-20
KR102696275B1 (ko) 2024-08-21
JP7194146B2 (ja) 2022-12-21
US20210061915A1 (en) 2021-03-04
EP3189074A1 (en) 2017-07-12
DK3189074T3 (da) 2021-04-19
CN107207577B (zh) 2021-11-09
EP3189074B1 (en) 2021-01-13
JP2020147568A (ja) 2020-09-17
RS61703B1 (sr) 2021-05-31
US20230265199A1 (en) 2023-08-24
JP6692816B2 (ja) 2020-05-13
CN113980116A (zh) 2022-01-28
JP2017527616A (ja) 2017-09-21
KR102869487B1 (ko) 2025-10-14
CA2960054C (en) 2023-11-14
CA2960054A1 (en) 2016-03-10
US20170283502A1 (en) 2017-10-05
PL3189074T3 (pl) 2021-08-02
ES2865488T3 (es) 2021-10-15
AU2015311563A1 (en) 2017-03-16
US20190359718A1 (en) 2019-11-28
SI3189074T1 (sl) 2021-08-31
US11649292B2 (en) 2023-05-16
AU2015311563B2 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
HRP20210577T1 (hr) Sastavi i načini liječenja i sprječavanje upale
Kumar et al. Protein aggregation and neurodegenerative diseases: From theory to therapy
Tan et al. Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
EA201991316A1 (ru) Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
BR112014008759A2 (pt) tratamento de doença ocular
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
CR20170060A (es) Anticuerpos anti tigit
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
JP2013520405A5 (https=)
JP2015517488A5 (https=)
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
EA201891710A1 (ru) Терапевтические соединения
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
BR112021019055A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
EA201391387A1 (ru) Нейропротекторные пептиды
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr